Personalized Medicine Does Not Fit In FDA's Current Scheme, Experts Say
This article was originally published in The Gray Sheet
Executive Summary
FDA's "old regulatory schemas" will not work for genetic and genomic testing and the broader field of personalized medicine, FDA Commissioner Margaret Hamburg admits
You may also be interested in...
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.